Literature DB >> 16194617

Optic atrophies in metabolic disorders.

Marjan Huizing1, Brian P Brooks, Yair Anikster.   

Abstract

Optic nerve involvement in metabolic disorders often results from apoptosis of cells that form or support the optic nerve, the retinal ganglion cell (RGC) axons, the myelin-forming oligodendrocytes, or the supporting vascular system. Given their high energy demands and the long course of their axons, RGCs are particularly sensitive to intracellular metabolic defects. Defects in energy metabolism, formation of reactive oxygen species, and storage of metabolites can all cause apoptosis of RGCs, decreased myelin formation of oligodendrocytes and increased pressure on the optic nerve. Clinically, the loss of RGC axons manifests as pale optic nerves. In general, the ophthalmologist can identify the underlying cause of an optic atrophy by careful examination, neuro-imaging, and family history. In some cases, however, the diagnosis proves elusive. In these instances, and especially when optic atrophy is accompanied by other systemic involvement, a metabolic disorder should be considered. Here, we review the underlying mechanisms of optic atrophy and its significance in metabolic disorders. Early identification of optic atrophy aids the diagnosis and subsequent management of the underlying condition, including anticipation of symptoms, genetic counseling, and possible therapeutic interventions. For many metabolic disorders, molecular testing is available.

Entities:  

Mesh:

Year:  2005        PMID: 16194617      PMCID: PMC8336112          DOI: 10.1016/j.ymgme.2005.07.034

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  94 in total

1.  Ophthalmologic aspects of lipid storage diseases.

Authors:  R O Brady
Journal:  Ophthalmology       Date:  1978-10       Impact factor: 12.079

Review 2.  The eye in metabolic disease.

Authors:  Ayman al-Khaier; Ken K Nischal
Journal:  Hosp Med       Date:  2003-10

Review 3.  Hereditary optic neuropathies.

Authors:  N J Newman; V Biousse
Journal:  Eye (Lond)       Date:  2004-11       Impact factor: 3.775

4.  The diagnostic yield of the evaluation for isolated unexplained optic atrophy.

Authors:  Andrew G Lee; Felix Y Chau; Karl C Golnik; Randy H Kardon; Michael Wall
Journal:  Ophthalmology       Date:  2005-05       Impact factor: 12.079

5.  Ocular histopathologic studies of neonatal and childhood adrenoleukodystrophy.

Authors:  S M Cohen; W R Green; Z C de la Cruz; F R Brown; H W Moser; M W Luckenbach; D J Dove; I H Maumenee
Journal:  Am J Ophthalmol       Date:  1983-01       Impact factor: 5.258

Review 6.  The pathogenesis of glycosphingolipid storage disorders.

Authors:  Luba Ginzburg; Yaacov Kacher; Anthony H Futerman
Journal:  Semin Cell Dev Biol       Date:  2004-08       Impact factor: 7.727

7.  Ocular manifestations of Niemann-Pick disease type B.

Authors:  Margaret M McGovern; Melissa P Wasserstein; Alan Aron; Robert J Desnick; Edward H Schuchman; Scott E Brodie
Journal:  Ophthalmology       Date:  2004-07       Impact factor: 12.079

8.  Ocular manifestations of the Smith-Lemli-Opitz syndrome.

Authors:  F L Kretzer; H M Hittner; R S Mehta
Journal:  Arch Ophthalmol       Date:  1981-11

9.  Pathophysiology of the optic neuropathy associated with Friedreich ataxia.

Authors:  Claron D Alldredge; Christopher R Schlieve; Neil R Miller; Leonard A Levin
Journal:  Arch Ophthalmol       Date:  2003-11
View more
  7 in total

1.  OPA3, mutated in 3-methylglutaconic aciduria type III, encodes two transcripts targeted primarily to mitochondria.

Authors:  Marjan Huizing; Heidi Dorward; Lien Ly; Enriko Klootwijk; Robert Kleta; Flemming Skovby; Wuhong Pei; Benjamin Feldman; William A Gahl; Yair Anikster
Journal:  Mol Genet Metab       Date:  2010-03-16       Impact factor: 4.797

2.  A model of Costeff Syndrome reveals metabolic and protective functions of mitochondrial OPA3.

Authors:  Wuhong Pei; Lisa E Kratz; Isa Bernardini; Raman Sood; Tohei Yokogawa; Heidi Dorward; Carla Ciccone; Richard I Kelley; Yair Anikster; Harold A Burgess; Marjan Huizing; Benjamin Feldman
Journal:  Development       Date:  2010-08-01       Impact factor: 6.868

3.  Comparative study of serine-plasmalogens in human retina and optic nerve: identification of atypical species with odd carbon chains.

Authors:  Kornél Nagy; Viral Vishnuprasad Brahmbhatt; Olivier Berdeaux; Lionel Bretillon; Frédéric Destaillats; Niyazi Acar
Journal:  J Lipid Res       Date:  2012-01-19       Impact factor: 5.922

4.  Biotinidase Deficiency, Bilateral Optic Atrophy, and a Visual Field Defect.

Authors:  Sarah Chamney; Vasuki Gnana Jothi; Eibhlin McLoone
Journal:  Neuroophthalmology       Date:  2013-11-19

5.  Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction.

Authors:  Sami Ellouze; Sébastien Augustin; Aicha Bouaita; Crystel Bonnet; Manuel Simonutti; Valérie Forster; Serge Picaud; Jose-Alain Sahel; Marisol Corral-Debrinski
Journal:  Am J Hum Genet       Date:  2008-09-04       Impact factor: 11.025

6.  Optic neuritis in a child with biotinidase deficiency: case report and literature review.

Authors:  Abdul-Aziz Hayati; Wan-Hazabbah Wan-Hitam; Min-Tet Cheong; Rohaizan Yunus; Ismail Shatriah
Journal:  Clin Ophthalmol       Date:  2012-03-13

7.  Two novel compound heterozygous mutations in OPA3 in two siblings with OPA3-related 3-methylglutaconic aciduria.

Authors:  Christina Lam; Linda K Gallo; Richard Dineen; Carla Ciccone; Heidi Dorward; George E Hoganson; Lynne Wolfe; William A Gahl; Marjan Huizing
Journal:  Mol Genet Metab Rep       Date:  2014-01-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.